Navigation Links
Amira Initiates Phase I Clinical Trial of Novel DP2 Antagonist
Date:4/20/2009

to treat inflammatory disease linked to the phospholipid pathways. Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease. Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions. Its scientific founders have successfully worked together for more than a decade and were pivotal in the discovery of a number of inflammatory drugs, including Singulair(R). The drug hunters at Amira are now actively leveraging their history of success to create high-value compounds for the future. For more information, visit www.amirapharm.com.


'/>"/>
SOURCE Amira Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related biology technology :

1. Amira Pharmaceuticals Hires Industry Veteran for CFO Position
2. Masimo Initiates Full Market Release of First-Ever Noninvasive Continuous Hemoglobin Monitor
3. Nereus Pharmaceuticals Initiates ADVANCE, a Randomized Phase 2 Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer
4. Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company
5. Cerimon Pharmaceuticals Initiates Phase III Clinical Studies to Evaluate Its Topical Diclofenac Sodium Patch for Mild-to-Moderate Pain
6. QRxPharma Initiates Second Comparative Study for MoxDuo(TM) IR Dual-Opioid(TM) Pain Therapy
7. Isis Initiates Phase 1 Clinical Trial of SGLT2 Antisense Drug
8. Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
9. China Bio-Immunity Corporation Initiates Voluntary Recalls of Rabies Vaccines
10. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
11. Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... 16 Decision Resources, one of the ... and healthcare issues, finds that, according to responses ... Abbott,s briakinumab (both interleukin inhibitors) will capture 22 ... the drug market for moderate to severe psoriasis. ... uptake, capturing nearly three times as much patient ...
(Date:12/16/2009)... Assessment with the Food and Drug Administration ... AEterna Zentaris Inc. (NASDAQ: AEZS ; ... company focused on oncology and endocrine therapy, ... Keryx Biopharmaceuticals Inc. ("Keryx") ( KERX), of ... perifosine (KRX-0401), the Company,s PI3K/Akt pathway inhibitor, ...
(Date:12/16/2009)... HSP A has been found to be effectinve in improving ... ... 2009 -- Nu-Tek BioSciences, LLC. ( www.nu-tekproducts.com ) is meeting the ... previously manufactured by Nutricepts, Inc. (Burnsville, Mn), is a high quality ... yields. HSP-A has been found to be especially effective in ...
(Date:12/15/2009)... BioEnergy Institute (JBEI), one of three Department of Energy ... time-stamping service to protect its valuable intellectual property. ... ... (PRWEB) December 15, 2009 -- Surety, LLC , ... , today announced that the Joint BioEnergy Institute (JBEI), ...
Breaking Biology Technology:In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market 2In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market 3AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 2AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 3AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 4AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 5Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 2Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 3Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 4Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 5
... 8 a.m. EDT -, SHENZHEN, China, Aug. 6 ... ) ("China Nepstar" or the "Company"), the,largest drugstore chain ... announced today the second quarter financial results ended June ... 2008., The Company will host a conference call, ...
... 5 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.,(NASDAQ: AEZS ... on,endocrine therapy and oncology, will announce its second ... on Tuesday, August 12,2008. The Company will host ... later that same day at 4:30 p.m., Eastern ...
... BEECH ISLAND, S.C., Aug. 6 Denham ... up to $60 million in VitAG,Corporation ("VitAG"). ... high-nitrogen fertilizer product capable of competing with ... the,construction of multiple biosolids-to-fertilizer manufacturing plants., ...
Other Biology Technology:China Nepstar Chain Drugstore to Announce Second Quarter 2008 Financial Results on August 27 2Denham Capital to Invest $60 Million in VitAG, Recycler of Municipal Biosolids 2
(Date:12/17/2009)... have discovered evidence that suggests a genetic variant may ... with asthma and adults who smoke, according to a ... Blood Institute (NHLBI), which is part of the National ... association between the genetic variant and a lowered risk ... who smoke. COPD is a lung disease most ...
(Date:12/17/2009)... accumulate excessive errors in the proteins they produce, ... cell suicide programme; however, beforehand the cells attempt ... rescue responses. Scientists know only the general outline ... interactions between them and the molecular components involved. ... (IRB Barcelona) have designed a new tool to ...
(Date:12/16/2009)... undergo a personality change in warmer water, according to ... make some species more aggressive. , Experiments with two ... have shown for the first time that some reef ... that these individual differences are even more marked as ... one or two degrees may have only a small ...
Breaking Biology News(10 mins):Media availability: Genetic variant may control lung function and risk of COPD 2Researchers design a tool to induce controlled suicide in human cells 2Researchers design a tool to induce controlled suicide in human cells 3Fish with attitude: Some like it hot 2Drunk Drivers May Respond to Brief Motivational Interview 62200 1Drunk Drivers May Respond to Brief Motivational Interview 62200 2Seniors May Need Help Overcoming Holiday Blues 62198 1Seniors May Need Help Overcoming Holiday Blues 62198 2FDA Approves Agriflu Seasonal Influenza Vaccine 6556 1FDA Approves Agriflu Seasonal Influenza Vaccine 6556 2
... When it comes to picking a mate, Crosby, Stills, Nash ... the one you love, love the one youre with. As ... the animal kingdom, too. , New research that crosses ... (to them) mates, females and males apparently have ways to ...
... to atherosclerosis a condition that greatly increases the risk ... of a key protein that protects the heart and blood ... have found. , Their findings could lead to new ... cause of death in the United States as well ...
... than 50 years ago as a way to improve ... Tennessee researcher to a significant finding about how animal ... , In the middle of the 20th century, local ... a new species of salamander to California water bodies. ...
Other Biology News:Species still have more viable offspring if they can choose their best mate 2Research explains link between cholesterol and heart disease 2UT researcher sheds new light on hybrid animals 2UT researcher sheds new light on hybrid animals 3
ID clarifier: platform...
The PROTEAN II xi multi-cell 2-D conversion kit converts the PROTEAN II xi multi-cell to the PROTEAN II XL multi-cell for a wider format cell that accepts 17 to 18 cm IPG strips....
The SVT3-2 diverter valve is a 3-port, 2-position valve for use with the BioLogic DuoFlow system....
... XL cell, wide format, is used for vertical electrophoresis ... gels and requires 1.2 L of running buffer. It ... 2.0 mm IPG conversion kit, which contains accessories for ... sets of IPG clamps, 2 sets of 20 x ...
Biology Products: